PharmaEssentia Corp (藥華醫藥), which provides drugs for a rare type of blood cancer, yesterday broke ground for a new factory in Hsinchu, which is scheduled to be completed in 2025.
The plant is expected to boost the company’s annual production value by NT$40 billion (US$1.25 billion), executives from the firm said at the groundbreaking ceremony.
The NT$5.1 billion plant is to comprise 50,000m2 to manufacture the polycythemia vera (PV) drug Ropeginterferon alfa-2b, also known as Ropeg.
Photo: CNA
PV is a rare blood cancer that causes bone marrow to produce excessive red blood cells and slows blood flow.
Approved by the US Food and Drug Administration in November last year, Ropeg is PharmaEassential’s most significant product, and helped boost the firm’s revenue to NT$2.04 billion in the first nine months, six times higher than a year earlier, the company said.
“Ropeg has gained approval in Taiwan, the EU, Switzerland, Israel, South Korea and the US. Now we are targeting Japan and China as the drug’s next markets,” PharmaEssentia chairwoman Teng Ching-leou (詹青柳) said at the ceremony.
The company is conducting a phase 3 clinical trial to determine whether Ropeg can also treat essential thrombocythemia, an uncommon disorder in which bone marrow produces too many platelets, Teng said.
PharmaEssentia would apply for market approval worldwide if the trial proves successful, she added.
The construction of the new plant in Hsinchu County’s Jhubei City (竹北) is expected to be finished in the first quarter of 2025, and enter mass production later that year after testing and an inspection by the US Food and Drug Administration, the company said.
PharmaEssentia also plans to partner with National Taiwan University Hospital’s branch in Hsinchu to develop cell therapy, the company added.
The company’s third-quarter revenue totaled NT$811 million, up 781 percent from a year earlier, while sales of Ropeg in the US continued to grow at a double-digit pace, it said.
Cairo’s new monorail slices across the city skyline, running above the familiar chaos of blaring horns and aging buses’ exhaust fumes that mark rush hour below. The US$4.5 billion monorail, opened this month, is among Egypt’s most prominent new transport projects, part of a debt-funded infrastructure drive criticized for sapping state finances while bringing limited benefits to most of the country’s 109 million people. “It feels like you’re in a different country,” said Ramy Sayed, a restaurant manager, aboard a driverless Innovia 300 train. “No noise, no traffic, we’re not used to this.” The eastern line runs 56km from the bustling middle-class
Taiwanese firms have increased investment in the Philippines in recent years as Manila’s ties with Washington deepen and global supply chains continue to shift away from China, an expert at the Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) said yesterday. The Philippines had not been among Taiwanese investors’ top choices in Southeast Asia, CIER Taiwan ASEAN Studies Center director Kristy Hsu (徐遵慈) said at a seminar in Taipei. However, Taiwan’s investment in the country has grown significantly since the COVID-19 pandemic, reaching US $257 million last year, a high in recent years, she said. Although Taiwan’s total investment in the Philippines still lags
Starlux Airlines Co (星宇航空) today unveiled a long-haul network expansion plan at a shareholders’ meeting in Taipei, including direct flights to Barcelona, Spain, and Zurich, Switzerland, as well as a service connecting Taipei, Sydney and New Zealand. Starlux is to become the first Taiwanese carrier to offer non-stop services to the two European cities, while the inaugural oceanic route is expected to expand transit opportunities within the Australia-New Zealand market, Starlux said. Flight services to Chicago, Dallas, Washington and New York are under evaluation, the airline added. Prior to the shareholders’ meeting, the airline earlier this year announced that it would be
Intel Corp regards Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) as a longstanding partner, as the US chipmaker would continue outsourcing production of advanced chips to TSMC, Intel chief executive officer Lip-Bu Tan (陳立武) said yesterday. “I don’t look at people as competitors. I look at the collaboration... Nvidia is also, you know, a good friend,” Tan told a news conference following his keynote speech at the Computex trade show in Taipei. “It’s a very trusted partnership for us... We are a big, top customer for them, and we’re going to continue doing that,” he said, referring to TSMC, the world’s largest foundry
RSS